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115* New targeting method for nucleic acid transfer into the lung
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Background: Nucleic acid transfer into the lung is a promising approach to
treat various acquired or hereditary lung diseases. Synthetic cationic vectors were
currently used for gene transfer to the lung but their high instability and toxicity
limited their efﬁcacy in vivo. Recently, we discovered a novel class of gene delivery
systems to the lung: nonionic block copolymers.
Aims: Our aim is to improve nucleic acid transfer efﬁciency of this novel class
of vectors. Recently, it was shown that galactose residues promoted the entry of
cationic vectors into human airway epithelial cells which mostly involved a receptor-
mediated endocytosis. Thus, galactose molecules will be covalently linked to the
extremities of block copolymers to speciﬁcally target airway epithelial cells through
galactose receptor recognition.
Methods: Galactosyl residues were grafted on block copolymers by chemical
synthesis. A CAT (chloramphenicol acetyl-transferase) reporter plasmid was for-
mulated with galactosylated block copolymers and injected in the lung of mice by
intratracheal instillation. After 2 days, reporter gene expression was evaluated in
lungs.
Results: A 30 fold increase of CAT expression is observed with galactosylated
block copolymers when compared to ungalactosylated block copolymers. Histo-
chemical and histopathological analysis will be performed to better understand the
enhancement of transfection efﬁcacy.
Conclusions: This new targeting method could improve transgene expression
in terms of efﬁciency and safety. Thus, we conclude that galactosylated block
copolymers could speciﬁcally deliver nucleic acid molecules to the airways of cystic
ﬁbrosis mice. Thus novel perspective for knockdown of speciﬁc gene in lung by
RNAi could be envisaged.
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The design of safe and efﬁcient vectors for gene delivery is a current challenge.
Viral-based systems are for now, one of the most efﬁcient methods to deliver genes
into the cells. However, immunogenic and oncogenic complications are two of
the main disadvantages of this transfection approach. As an alternative, synthetic
carriers have been developed, notably based on cationic lipids.
Our objective was to evaluate the in vivo transfection capacity of three cationic
carriers that (KLN47, EP8e, BSV-18) differ by the nature of their hydrophobic
domain, respectively oleyl, linoleyl and phytanyl chains. Formulated in NaCl 0.9%,
they are associated with 50mg of pDNA encoding Luciferase. Then, lipoplexes are
injected into the tail vein of mice and Luc expression was analysed up to 72 h by in
vivo bioluminometer (NightOwl II, Berthold). We ﬁrst observed that Luc expression
was exclusively located into the lungs. Secondly, the highest transgene expression
was obtained 24 h after transfection and progressively decreased. Thirdly, EP8e and
BSV-18 were much more efﬁcient than KLN47. Moreover, contrary to KLN47, both
new vectors did not induce any mice death and their lower toxicity was conﬁrmed
by ALAT/ASAT measurements. The structure-activity relationship is crucial for a
gain of effectiveness and inocuity.
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Development of non-toxic and efﬁcient gene delivery systems is among the most
challenging requirement for gene therapy. Synthetic carriers have been developed
for their non-immunogenicity, as well as for their easiness of handling. Lipids
and polymers have so far demonstrated their effectiveness and linear PEI (lPEI)
was found to offer opportunity to treat cystic ﬁbrosis. Herein, we designed lPEI
derivatives bearing histidinyl moieties to increase the buffering effect of lPEI in
order to facilitate the endosome escape of the polyplexes. First, grafting of the amino
acid was conducted through the Mickael addition of the N-acryloyl-L-histidine on
the secondary amine of the polymer. Grafting was set between 4 and 50% and this
was veriﬁed through 1H and 13C NMR. In vitro transfections with various cell
lines, including human pulmonary cells (A549 and 16HBE), indicated that, when
mixed with a luciferase encoding plasmid, His-lPEI characterized with a histidine
content of 25 mol % was able to reach the highest luciferase activities. Compared to
unmodiﬁed lPEI, this new polymer was at least as efﬁcient while the toxicity level
was remarkably very reduced. In vivo gene delivery experiments in mice, via either
systemic or intranasal administration routes, demonstrated the effectiveness of this
His-lPEI to transfect the lungs and conﬁrmed its low toxicity. Thus, histidinylated
lPEI derivatives may constitute promising weakly toxic non-viral vectors for lung
gene therapy of cystic ﬁbrosis.
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Background: CFTR, the gene mutated in cystic ﬁbrosis (CF), was the ﬁrst human
gene to be delivered to patients using Adenovirus serotype 5 (Ad5) vector and
these clinical trials have revealed several limitations of Ad5 vectors. In this study,
the gene delivery of GFP-CFTR by a chimeric Ad5Fi35 vector to human airway
epithelial and tracheal cells was analyzed for transduction efﬁciency, correction of
chloride channel activity, GFP-CFTR cellular localization and vector toxicity.
Methods: Transduction efﬁciency by Ad vectors was assayed by ﬂow cytometry,
cellular trafﬁcking of GFP-CFTR by confocal ﬂuorescence microscopy, CFTR
function by a radiotracer ﬂux method and by measure of transepithelial ion transport.
Results: High doses of Ad5 vector was detrimental to the endogenous CFTR
function in normal cells transduced by Ad5GFP, and to exogenous CFTR delivered
by Ad5GFP-CFTR in CFTR(−) cells. This inhibition of CFTR function was
associated with the viral capsid proteins involved in the RGD-integrin cell entry
pathway used by the vector.
A chimeric vector, Ad5Fi35GFP-CFTR which uses a RGD-independent cell entry
pathway, showed minimum effect on CFTR function even at high doses. More
importantly, Ad5Fi35-GFP-CFTR transduced reconstituted airway epithelia from
CF patients via the apical surface and restored the CFTR function at relatively low
vector doses.
Conclusion: Ad5Fi35 represents a potential vector for efﬁcient gene delivery to
the airway epithelium.
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